£100M market cap. (62P)28 Apr 2020 12:25
Sorry about that, wrong button lol!
Blue Earth Diagnostics was purchased for £354.3m last year by Bracco Imaging. By comparison Polarean has exposure to a market that is 10x bigger than what Blue Earth was targeting in the US alone. Bracco Imaging is now a strategic partner with a 7.6% position in the company. We are expecting further updates on how Bracco Imaging is to become (IMO) of more importance to POLX in terms of expansion into Europe and its subsequent approval. Dr. Allis who was once the CEO of blue earth diagnostics has just become Chairman of POLX and has significant skin in the game having been involved with the IP before it came out of GE. All just screams confidence.
High Margins
- System selling price including RF Coils - $475,000 with a gross margin of 60%
- Price paid to Polarean per dose Xenon - $240 with a gross margin of 70%
- Service contact per annum - $40,000 with a gross margin of 50%
- Application software per annum - $50,000 with a gross margin of 90%
You can quickly see why the razor blade model of POLX will fast generate both one off and more importantly recurring revenue per scan under hatch waxman making the potential numbers mind blowing for anyone prepared to hold onto this stock prior to the inevitable takeover at many multiples of todays price, let alone £100m.
Now fully funded until FDA approval, I often use the likes of STX and its share price on the lead up to FDA approval as a guide for POLX, especially given the Pre-NDA reducing the risk of approval significantly. I have heard many say that they will come back as they don't expect much to happen between now and approval. Well imo the story has only just begun and the price will follow as it unfolds.
Sign In
Follow the stocks
